Exagen (XGN) Earnings Date & Reports

Key Takeaways

• Exagen reported third quarter 2026 revenue of $18.4 million, up 7% year over year and slightly ahead of analyst consensus estimates.
• GAAP net loss per share was $0.25, a wider loss than the roughly $0.19 analysts had expected.
• AVISE® CTD test volume rose only 2% year over year, a sharp deceleration from double-digit growth earlier in 2026, while pricing continued to climb.
• Management reiterated full-year 2026 revenue guidance of $72 million to $75 million, implying 8% to 13% annual growth.
• For more detail, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Interested in automated market insights? Explore Trending AI Robots.

Earnings Context and Why It Matters

Exagen Inc. (Nasdaq: XGN) is a precision medicine and diagnostics company whose flagship AVISE® CTD test helps physicians diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's disease. This quarter matters because investors have been watching whether the company can sustain momentum after several years of double-digit revenue growth. Heading into the report, the focus was on test volume trends, average selling price (ASP) improvements, and progress toward the anticipated early-2027 launch of a new myositis test. With growth increasingly driven by pricing rather than volume, the results offered a critical read on the durability of Exagen's commercial strategy.

Reported Results

For the third quarter ended September 30, 2026, Exagen reported revenue of $18.4 million, a 7% increase from $17.2 million in the prior-year period and slightly above consensus estimates of roughly $18.3 million. GAAP net loss narrowed to $6.3 million, or $0.25 per share, compared with a loss of $7.1 million, or $0.31 per share, a year earlier. However, the per-share loss was wider than the approximately $0.19 consensus estimate.

Volume and pricing diverged notably. AVISE® CTD test volume grew just 2% year over year, down from roughly 10% in the first quarter of 2026, while trailing twelve-month ASP (average selling price) reached $451 per test, marking a 14th consecutive quarterly increase. Gross margin improved modestly to about 59%. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) showed a loss of $1.9 million, roughly flat versus the prior year. The company ended the quarter with cash and equivalents of just over $28 million.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion to earnings research. Explore the AI Screener to refine your watchlist.

Market Reaction and Investor Sentiment

Exagen shares fell sharply following the report, as investors weighed the top-line beat against a wider-than-expected loss and, more importantly, the slowdown in test volume growth. The single-digit volume increase, coupled with slowing growth in ordering physicians, raised questions about whether the company's commercial expansion can return to double-digit rates. Sentiment was further tempered by the reliance on pricing and older-claim collections to drive ASP gains, alongside a modest gross margin improvement that delivered limited operating leverage for the quarter. The reiterated full-year revenue guidance provided some reassurance, but the decelerating volume trend dominated the immediate market interpretation.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching several catalysts tied to Exagen's transition from a single-product focus toward a broader autoimmune testing platform. The most closely followed item is the myositis test, which completed analytical and clinical validation during the quarter, with a regulatory submission to the New York State Department of Health expected by the end of January 2027 and a launch targeted for early 2027.

Beyond myositis, the company's pipeline includes work on rheumatoid arthritis disease activity monitoring, lupus nephritis testing, and systemic lupus erythematosus disease activity assessment. Management has signaled a strategy of pairing these internal projects with an expanding Pharma Services business, whose year-to-date revenue grew roughly 85% to $2.2 million on a contract backlog of about $5.5 million.

Key factors to monitor include whether AVISE® CTD volume growth reaccelerates, whether ASP gains remain sustainable given potential regulatory changes to reimbursement, and how operating expenses trend as the company invests ahead of the myositis launch. Progress on gross margin toward management's mid-60% target and the company's ability to preserve its cash position will also be important signals for the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations